Skip to content

Viatris VTRS Long-Term Debt

Long-Term Debt at other companies

Pfizer logo
PfizerPFE
$60.57B+5.1%
McKesson logo
McKessonMCK
$6.6B+17.9%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$286M-6.3%
Cencora logo
CencoraCOR
$12.18B+71.9%
AMP
Amphastar PharmaceuticalsAMPH
$609.8M+1.0%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$45M0.0%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$20.8B+92.8%
Enterprise value$33.61B+34.5%
P/S1.4×+0.7×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's long-term debt?
Viatris (VTRS) reported long-term debt of $12.41B in Q1 2026.
How has Viatris's long-term debt changed year-over-year?
Viatris's long-term debt decreased by 12.4% year-over-year, from $14.18B to $12.41B.
What is the long-term trend for Viatris's long-term debt?
Over 5 years (2020 to 2025), Viatris's long-term debt has grown at a -11.1% compound annual growth rate (CAGR), from $22.43B to $12.48B.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.